R&D Trends

PrimeraDx, Quest Diagnostics to develop companion diagnostics

Wednesday, March 27, 2013 10:26 AM

PrimeraDx, a molecular diagnostics company, has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics, a diagnostics information services company. The intent of the collaboration is to co-develop and commercialize molecular diagnostic products and services with a focus on supporting clinical development of targeted therapeutics for drug developers.

More... »

Spinifex receives $1.5M in R&D tax incentive relating to pain research

Wednesday, March 27, 2013 09:28 AM

Spinifex Pharmaceuticals, an Australian pain drug development company, has received an approximately $1.5 million R&D tax incentives cash refund for research activities relating to the discovery of new drugs for the treatment and management of pain.

More... »

Survey underscores importance of patient education and engagement in personalized medicine

Monday, March 25, 2013 02:17 PM

Nearly two out of three people in four major European countries have no awareness of personalized medicine—despite the fact that this evolving discipline has vast implications for Europe's healthcare issues and Europeans' personal health.

More... »

Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments

Monday, March 25, 2013 12:24 PM

Global healthcare company Sanofi and biopharmaceutical company Transgene have signed a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene's therapeutic products.

More... »

Third Rock Ventures raises $516M Fund III

Monday, March 25, 2013 11:56 AM

Third Rock Ventures, a venture capital firm, announced the final closing of Fund III, raising $516 million in an oversubscribed fund. With Fund III, Third Rock will continue to execute on its strategy of launching, building and supporting transformative healthcare companies.

More... »

Astellas inks two new dengue virus research collaborations

Monday, March 25, 2013 10:30 AM

Global pharmaceutical company Astellas Pharma has signed collaborative research agreements with both the Nagasaki University and the Tokyo Institute of Technology, both located in Japan, regarding the dengue virus.

More... »

Shire to acquire SARcode Bioscience, expand presence in ophthalmology

Monday, March 25, 2013 09:42 AM

Global specialty biopharmaceutical company Shire has agreed to acquire SARcode Bioscience, a Brisbane, Calif.-based privately held biopharmaceutical company. The acquisition continues to build Shire's presence in the ophthalmology therapeutic category and brings a new phase III compound—Lifitegrast—currently under development for the signs and symptoms of dry eye disease, into Shire's portfolio.

More... »

H3 Biomedicine, BGI Announce to develop, share cancer genomic sequencing data

Friday, March 22, 2013 03:33 PM

H3 Biomedicine, a biopharmaceutical company specializing in oncology treatments, and BGI, the largest genomics organization in the world, have entered into a partnership to sequence and publish genomic data from pre-clinical cancer models.

More... »

AstraZeneca, Moderna Therapeutics to develop pioneering messenger RNA Therapeutics

Friday, March 22, 2013 10:51 AM

AstraZeneca, a global biopharmaceutical company, has formed an exclusive agreement with Moderna Therapeutics, a Cambridge-Mass.-based biopharmaceutical company, to discover, develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer.

More... »

bluebird bio collaborates with Celgene to advance gene therapy in oncology

Friday, March 22, 2013 10:23 AM

bluebird bio, a Cambridge-Mass.-based privately-held biotechnology company focused on gene therapy, has formed a broad, global strategic collaboration with Celgene, a Summit, N.J.-based integrated global biopharmaceutical company focused on cancer and inflammatory diseases, to discover, develop and commercialize novel disease-altering gene therapies in oncology.

More... »